Danaher (DHR) revenue breakdown
By segment, Diagnostics is the largest at 40% of fiscal 2025 revenue, growing 7% a year over 7 years.
By product, Recurring is the largest at 82% of fiscal 2025 revenue, growing 1% a year over 4 years.
Revenue by segment
Fiscal years, as Danaher reports them in its 10-K filings; fiscal 2025 total $24.6B.
| Segments | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $6.3B | $6.6B | $7.4B | $9.8B | $10.8B | $9.6B | $9.8B | $9.9B | 40% |
| Life Sciences | $6.5B | $7.0B | $5.3B | $6.4B | $7.0B | $7.1B | $7.3B | $7.3B | 30% |
| Biotechnology | — | — | $5.3B | $8.6B | $8.8B | $7.2B | $6.8B | $7.3B | 30% |
| Environmental & Applied Solutions | $4.3B | $4.4B | $4.3B | — | — | — | — | — | — |
Revenue by product
Fiscal years, as Danaher reports them in its 10-K filings; fiscal 2025 total $24.6B.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Recurring | — | — | — | $19.1B | $20.9B | $18.7B | $19.4B | $20.1B | 82% |
| Nonrecurring | — | — | — | $5.7B | $5.8B | $5.2B | $4.5B | $4.4B | 18% |
| Research and medical products | $12.7B | $13.5B | $18.0B | — | — | — | — | — | — |
| Analytical and physical instrumentation | $2.4B | $2.5B | $2.4B | — | — | — | — | — | — |
| Product Identification | $1.9B | $1.9B | $1.9B | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Danaher reports them in its 10-K filings; fiscal 2025 total $24.6B.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| North America | $6.5B | $7.0B | $9.0B | $9.8B | $11.7B | $10.0B | $10.3B | $10.4B | 42% |
| High-growth markets | $5.4B | $5.7B | $6.7B | $7.8B | $7.7B | $7.2B | $6.9B | $7.0B | 29% |
| Western Europe | $4.1B | $4.1B | $5.3B | $5.9B | $5.9B | $5.5B | $5.5B | $5.9B | 24% |
| Other developed markets | $1.1B | $1.1B | $1.3B | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | 5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DHR.
Open DHR in InvestinglyQuestions
Where does Danaher make its money?
In fiscal 2025, by segment: Diagnostics $9.9B, Life Sciences $7.3B, Biotechnology $7.3B.
From Danaher's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.